SCHEMBL4133876

SCHEMBL4133876

CC1CCN(C(=O)CCn2c3c(c4cc(Cl)ccc42)CN(C)CC3)CC1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BAZ2B Q9UIF8 5/20 0.59
HDAC1 Q13547 3/20 0.55
HDAC6 Q9UBN7 3/20 0.55
CNR1 P21554 6/20 0.49
GRIN2B Q13224 1/20 0.49
ACHE P22303 1/20 0.48
PTGDR2 Q9Y5Y4 1/20 0.46
HTR6 P50406 2/20 0.44
MAOA P21397 1/20 0.44
MAOB P27338 1/20 0.44
ADRA2A P08913 1/20 0.44
HTR2A P28223 1/20 0.44
HTR2C P28335 1/20 0.44
HTR7 P34969 1/20 0.44
ADRA1A P35348 1/20 0.44
HRH1 P35367 1/20 0.44
CNR2 P34972 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3724789 0.91 BAZ2B (0.57) BAZ2BHDAC1HDAC6CNR1PTGDR2
SCHEMBL3717390 0.90 BAZ2B (0.63) BAZ2BHDAC1HDAC6GRIN2BACHE
SCHEMBL16622112 0.89 HRH1 (0.58) HDAC1HDAC6CNR1GRIN2BACHE
SCHEMBL4130679 0.89 BAZ2B (0.62) BAZ2BHDAC1HDAC6GRIN2BACHE
SCHEMBL4144526 0.87 BAZ2B (0.60) BAZ2BHDAC1HDAC6GRIN2BACHE
SCHEMBL13696251 0.86 BAZ2B (0.56) BAZ2BHDAC1HDAC6GRIN2BACHE
SCHEMBL3237875 0.84 BAZ2B (0.53) BAZ2BHDAC1HDAC6CNR1PTGDR2
SCHEMBL13534396 0.83 BAZ2B (0.68) BAZ2BHDAC1HDAC6GRIN2BACHE
SCHEMBL3316657 0.83 BAZ2B (0.78) BAZ2BHDAC1HDAC6GRIN2BACHE
SCHEMBL4304853 0.83 POLB (0.49) BAZ2BHDAC1HDAC6CNR1PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181240-B2 Tetracyclic compounds MEDIVATION TECHNOLOGIES, INC. (US) 2015-11-10 US disclosed
US-9096591-B2 Tetracyclic compounds MEDIVATION TECHNOLOGIES, INC. (US) 2015-08-04 US disclosed
US-9096591-B2 Tetracyclic compounds MEDIVATION TECHNOLOGIES, INC. (US) 2015-08-04 US disclosed
US-9096591-B2 Tetracyclic compounds MEDIVATION TECHNOLOGIES, INC. (US) 2015-08-04 US disclosed
US-20150182509-A1 TETRACYCLIC COMPOUNDS MEDIVATION TECHNOLOGIES, INC. 2015-07-02 US disclosed
US-20150182509-A1 TETRACYCLIC COMPOUNDS MEDIVATION TECHNOLOGIES, INC. 2015-07-02 US disclosed
US-20150182509-A1 TETRACYCLIC COMPOUNDS MEDIVATION TECHNOLOGIES, INC. 2015-07-02 US disclosed
US-9034880-B2 Tetracyclic compounds MEDIVATION TECHNOLOGIES, INC. (US) 2015-05-19 US disclosed
US-9034880-B2 Tetracyclic compounds MEDIVATION TECHNOLOGIES, INC. (US) 2015-05-19 US disclosed
US-9034880-B2 Tetracyclic compounds MEDIVATION TECHNOLOGIES, INC. (US) 2015-05-19 US disclosed
US-20130190304-A1 TETRACYCLIC COMPOUNDS MEDIVATION TECHNOLOGIES, INC. (US) 2013-07-25 US disclosed
US-20130190304-A1 TETRACYCLIC COMPOUNDS MEDIVATION TECHNOLOGIES, INC. (US) 2013-07-25 US disclosed
US-20130131054-A1 TETRACYCLIC COMPOUNDS MEDIVATION TECHNOLOGIES, INC. (US) 2013-05-23 US disclosed
US-8338408-B2 Tetracyclic compounds MEDIVATION TECHNOLOGIES, INC. (US) 2012-12-25 US disclosed
US-8338408-B2 Tetracyclic compounds MEDIVATION TECHNOLOGIES, INC. (US) 2012-12-25 US disclosed
US-8338408-B2 Tetracyclic compounds MEDIVATION TECHNOLOGIES, INC. (US) 2012-12-25 US disclosed
US-20090239854-A1 Tetracyclic compounds MEDIVATION TECHNOLOGIES, INC. 2009-09-24 US disclosed
US-20090239854-A1 Tetracyclic compounds MEDIVATION TECHNOLOGIES, INC. 2009-09-24 US disclosed
US-20090239854-A1 Tetracyclic compounds MEDIVATION TECHNOLOGIES, INC. 2009-09-24 US disclosed
WO-2009055828-A1 NEW TETRACYCLIC COMPOUNDS MEDIVATION TECHNOLOGIES, INC. (US) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150182509-A1 TETRACYCLIC COMPOUNDS HTR2C, HTR3D, HTR5A BAZ2B 2213/4885HDAC1 4146/4885HDAC6 2884/4885
US-20130131054-A1 TETRACYCLIC COMPOUNDS HTR2C, HTR3D, HTR5A BAZ2B 2213/4885HDAC1 4146/4885HDAC6 2884/4885
US-20130190304-A1 TETRACYCLIC COMPOUNDS HTR2C, HTR3D, HTR5A BAZ2B 2213/4885HDAC1 4146/4885HDAC6 2884/4885
US-20090239854-A1 Tetracyclic compounds HTR2C, HTR3D, HTR5A BAZ2B 2213/4885HDAC1 4146/4885HDAC6 2884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.